Abstract
An increasing number of laboratories that focus on model systems are considering drug screening. Executing a drug screen is complicated enough. But the path for moving initial hits towards the clinic requires a different knowledge base and even a different mindset. In this Editorial I discuss the importance of doing some homework before you start screening. 'Lead hits', 'patentable chemical space' and 'druggability' are all concepts worth exploring when deciding which screening path to take. I discuss some of the lessons I learned that may be useful as you navigate the screening matrix.
Original language | English |
---|---|
Pages (from-to) | 1241-1244 |
Number of pages | 4 |
Journal | DMM Disease Models and Mechanisms |
Volume | 9 |
Issue number | 11 |
DOIs | |
State | Published - 1 Nov 2016 |